A groundbreaking universal vaccine is currently in development to safeguard against entire groups of viruses and prevent potential future pandemics. British scientists are utilizing artificial intelligence (AI) to create this innovative vaccine, which aims to provide protection against future virus mutations. Traditionally, viruses evolve over time, rendering current vaccines less effective and necessitating constant updates.
Researchers at Cambridge and Southampton universities have introduced a revolutionary vaccine that viruses cannot easily mutate to evade immunity, thus potentially averting pandemics and eliminating the need for future lockdowns. Initial trials have demonstrated the safety of a coronavirus vaccine developed using advanced technology, prompting the upcoming launch of the second phase of the trial.
The development of the vaccine involved leveraging AI to analyze global data on historical virus mutations, identifying a crucial “super antigen” on the viral molecule essential for the survival of similar viruses. Professor Saul Faust, the lead investigator from Southampton University, highlighted the continuous evolution of viruses like flu, coronaviruses, and the Ebola group, emphasizing the limitations of the current reactive vaccine system.
The universal vaccine, named Sarbeco, was tested on 49 healthy volunteers aged 18 to 50 in Cambridge and Southampton in collaboration with biotechnology company DIOSynVax. Administered as a DNA vaccine through a needle-free micro fluid jet method, the vaccine was found to be safe and capable of eliciting an immune response not only against SARS-CoV-2 and SARS but also related bat viruses with zoonotic potential.
Professor Jonathan Heeney, co-author from Cambridge’s lab of viral zoonotics, emphasized the need to shift from the traditional vaccine paradigm to a more comprehensive approach that targets essential elements shared among virus families. The upcoming phase II trial will involve over 200 volunteers to further evaluate the vaccine’s efficacy.
Prof Heeney expressed optimism that this innovative technology could revolutionize viral protection by offering broad immunity against numerous virus variants, including Ebola. The study, sponsored by University Hospital Southampton NHS Foundation Trust, has been hailed as a significant advancement in creating lasting viral protection by Prof Marian Knight, the scientific director for the National Institute for Health and Care Research (NIHR) Infrastructure.
